|Type||Single-chain variable fragment|
|Bioavailability||Not applicable (IV only)|
|Elimination half-life||1–2 hours|
|Chemical and physical data|
|Molar mass||Approximately 27.2 kg/mol|
|(what is this?)|
Efungumab (trade name Mycograb) is a drug developed by NeuTec Pharma (a subsidiary of Novartis), intended to treat invasive Candida infection in combination with amphotericin B. The European Medicines Agency has twice refused to grant marketing authorization for Mycograb, citing product safety and quality issues.
Its ability to potentiate the effects of the antifungal amphotericin B in culture were later found to be non-specific.
- European Medicines Agency (2007). "REFUSAL CHMP ASSESSMENT REPORT FOR MYCOGRAB. Procedure No. EMEA/H/C/658" (PDF). (370 KiB). London: European Medicines Agency. Retrieved on 2007-11-20. Detailed assessment report with comprehensive overview of reasons for refusal of marketing authorization.
- World Health Organization (2006). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 95" (PDF). WHO Drug Information. 20 (2): 48.
- Richie DL, Ghannoum MA, Isham N, Thompson KV, Ryder NS (2012). "Nonspecific effect of Mycograb on amphotericin B MIC". Antimicrob. Agents Chemother. 56 (7): 3963–4. doi:10.1128/AAC.00435-12. PMC 3393390. PMID 22508314.
|This antiinfective drug article is a stub. You can help Wikipedia by expanding it.|
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|